Our Mission 

Attogen Biomedical Inc. (“AttoBio” in short)
Located in the beautiful lake area of Suzhou Industrial Park (SIP), AttoBio holds the official certificate of “National High-tech Enterprise” in China. 
Focused on women’s health market, company strives to advance the technology to solve the unmet needs in cancer prevention and early diagnosis.  Currently, company offers to the clinical market with a comprehensive product line, all of which obtained clinical approval from NMPA (National Medical Product Administration, previously CFDA).  AttoBio product catalog consists of specialty biomarkers for cervical cancer early detection (E6/E7 oncoprotein antibody reagents) and more than 50 other tumor markers for immunohistochemical assays. To meet the high demand in the growing market of clinical pathology, AttoBio also developed laboratory automation instruments, immunochemical slide ICC/IHC stainer and digital pathology image scanner, and related software APP packages and AI algorithms. Company aims to deliver high quality products with advanced technology and user-friendly features to improve the work efficiency of pathology lab professionals, ultimately to benefit our patients for better health and quality of life.   
Company holds formal license for medical device manufacture facility, GMP (Good Manufacturing Practice) since 2014. Company established quality management system with the quality insurance and certification ISO13485, also obtained CE Marks for several IVD products since 2016. Company operation strictly abides by the legal laws and regulatory rules of the NMPA. 
AttoBio is today a fast-growing and fully integrated biotech enterprise, with functional divisions for R&D, manufacture, regulatory compliance, and a marketing and sales team for commercialization of its own products. 
Our mission is to commit our efforts for the great cause of eliminating cervical cancer from human race in 21century.